Jeffrey Skolnik, MD Inovio Pharmaceuticals discusses the Empower the Immune System to Treat Glioblastoma: DNA as Medicine.
Information:
* Explore DNA drugs that can produce robust, antigen-specific T cell reactions
Evaluating the DNA medicine of Inovio, INO-5401 has promising early GBM data suggesting early efficacy and immunogenicity.
Discuss the DNA medication of Inovio, its technology, and other promising approaches to GBM therapy.
Dr. Skolnik supervises all the cancer immunotherapy services for Inovio, as well as those for other infectious diseases. Formerly at Tetralogic Pharmaceuticals, where he was Vice President of Clinical Research and later Chief Medical Officer, Dr. Skolnik supervised all oncology, infectious diseases, and dermatology clinical services. He was also an oncology pioneer in Medical Affairs at GSK and held many positions at AstraZeneca, including Senior Director for both early and late-stage compounds. Dr. Skolnik is also a pediatric haematologist and has written many articles on the nature of pediatric oncology trials.